Regularly scheduled FET PET scans over extended periods help clinicians confidently monitor fluctuating lesions. This longitudinal data provides the reassurance needed to be patient and avoid prematurely escalating treatment for what may ultimately prove to be benign, treatment-related changes.
In low-grade gliomas, FET PET can pinpoint metabolically active regions within larger, non-specific areas of flare signal abnormality. This helps neurosurgeons target biopsies or resections to the most aggressive parts of the tumor, potentially identifying transformation to a higher grade.
The intensity and volume of FET PET activity serve as a powerful prognostic marker in glioma patients. Even when imaging suggests treatment-related changes rather than active tumor, elevated PET signals still correlate with a worse overall outcome, providing an additional layer of risk stratification.
In cases of suspected glioma recurrence post-radiation, FET PET imaging can provide a more accurate diagnosis than MRI perfusion, even when MRI findings suggest tumor growth. This allows clinicians to avoid unnecessary changes in therapy based on potentially misleading MRI data.